This is a review about SMAD2, based on 53 published articles (read how Labome selects the articles), using SMAD2 antibody in all methods. It is aimed to help Labome visitors find the most suited SMAD2 antibody.
SMAD2 synonym: JV18; JV18-1; MADH2; MADR2; hMAD-2; hSMAD2; MAD homolog 2; SMAD, mothers against DPP homolog 2; Sma- and Mad-related protein 2; mother against DPP homolog 2; mothers against decapentaplegic homolog 2

EMD MilliporeEMD Millipore SMAD2 product
  • immunohistochemistryIn 2009, Akiyoshi Komuro et al. employed EMD Millipore Smad2 antibody to investigate the role of transforming growth factor Beta signaling in the regulation of tumor growth [ncbi , more ]. In 2008, Miguel A Alejandre-Alcázar et al. used EMD Millipore Smad2 antibody to perform immunohistochemistry and western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ]. In 2005, Takayuki Furumatsu et al. used EMD Millipore Smad2 antibody to study chondrogenesis Induction by Smad3 [ncbi , more ]. In 2002, Chunming Dong et al. utilized EMD Millipore Smad2 antibody to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ].
  • western blotIn 2009, Marcela Guzman-Ayala et al. utilized EMD Millipore Smad2 antibody to demostrate that the target gene expression can be promoted through Smad2/3 activation [ncbi , more ]. In 2008, Miguel A Alejandre-Alcázar et al. used EMD Millipore Smad2 antibody to perform immunohistochemistry and western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ]. In 2006, Anna Sergeeva et al. used EMD Millipore Smad2 antibody to perform western blot assays in order to investigate the molecular regulation mechanisms of Smad4 in the process of normal pancreas development and pancreatic ductal adenocarcinomas (PDAC) growth (catalog: AB3849) [ncbi , more ]. In 2005, Nichole Boyer Arnold et al. applied EMD Millipore Smad2 antibody to study COLO-357 cell growth inhibition by TGF beta1 [ncbi , more ]. EMD Millipore Smad2 antibody was utilized in 2004 to study the pituitary prolactin expression and cell growth inhibited by activin [ncbi , more ], to study the impaired Smad7-Smurf mediated negative regulation of TGF- signaling in scleroderma fibroblasts [ncbi , more ]and to study expression of nodal, lefty-A, and lefty-B in undifferentiated human embryonic stem cells [ncbi , more ]. Wen Bin Chen et al. used EMD Millipore Smad2 antibody to study the involvement of Smad proteins in the TGF-beta control of BGN and SLRP gene expression [ncbi , more ] in 2002 and Chunming Dong et al. used EMD Millipore Smad2 antibody to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ]. In 2001, H Watanabe et al. utilized EMD Millipore Smad2 antibody to Smad, ERK1/2, and p38 mitogen-activated protein kinase pathway cross-talka in chondrogenic ATDC5 cells [ncbi , more ].
Cell Signaling TechnologyCell Signaling Technology SMAD2 product
  • immunohistochemistryIn 2009, Minghua Wu et al. utilized Cell Signaling Technology Smad2 antibody to investigate the role of PPAR-gamma in the regulation of bleomycin induced scleroderma [ncbi , more ]. In 2007, Lanying Song et al. utilized Cell Signaling Technology Smad2 antibody to study the role of Alk3 during AV cushion morphogenesis in mouse embryonic hearts [ncbi , more ]. In 2003, Dirk Haller et al. used Cell Signaling Technology Smad2 antibody to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ].
  • western blotIn 2010, David J Shields et al. utilized Cell Signaling Technology Smad2 antibody to perform western blot in order to study the roles of RBBP9 as a tumor-associated serine hydrolase to pancreatic neoplasia [ncbi , more ]. Cell Signaling Technology Smad2 antibody was employed in 2009 to carry out western blot analysis in order to investigate the role for Smurf2 in promoting breast cancer metastasis [ncbi , more ], to investigate the role of ALK5 in the regulation of pulmonary arterial hypertension [ncbi , more ], to test a hypothesis that activin C antagonizes the effects of activin A and its overexpression leads to pathologies [ncbi , more ]and to perform westn blot in order to investigate the relations between TGFbeta1 and TNFa [ncbi , more ]. In 2008, Savita Bharathy et al. utilized Cell Signaling Technology Smad2 antibody to perform western blot in order to show the mechanism that two functions of TGF become un-coupled during cancer development [ncbi , more ]. Cell Signaling Technology Smad2 antibody was used in 2007 to study the role of acetylation, one of the main post-translational regulatory mechanisms, in regulating Fli1 activity in human dermal fibroblast [ncbi , more ], to study the role of disintegrin and metalloproteinase ADAM12 in TGF-beta signaling through interaction with the type II receptor [ncbi , more ]and to study the role of Alk2 in activin signaling [ncbi , more ]. In 2005, Hendrik Ungefroren et al. utilized Cell Signaling Technology Smad2 antibody to study phospholation of Smad2 by caALK5 [ncbi , more ]. Cell Signaling Technology Smad2 antibody was employed in 2004 to study the role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis [ncbi , more ], to detect phospho-Smad8 in human fibroblastic cells infected with recombinant adenovirus vectors carrying ALK5CA [ncbi , more ]and to study expression of nodal, lefty-A, and lefty-B in undifferentiated human embryonic stem cells [ncbi , more ]. Cell Signaling Technology Smad2 antibody was utilized in 2003 to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ], to study the effect of transforming growth factor- 1 mutations on the action of TGF- 1 in vitro [ncbi , more ]and to study Cripto roles in tumor cell growth in vivo [ncbi , more ].
Life Technologies CorporationLife Technologies Corporation SMAD2 product
  • immunocytochemistryIn 2009, Derek P Simon et al. applied Life Technologies Corporation Smad2 antibody to be dually phosphorylated at Ser465 and Ser467 in order to study the mechanism of activin receptor signaling regulating prostatic epithelial cell adhesion and viability [ncbi , more ]. In 2005, Nichole Boyer Arnold et al. applied Life Technologies Corporation Smad2 antibody to study COLO-357 cell growth inhibition by TGF beta1 [ncbi , more ].
  • immunoprecipitationIn 2002, Susan Fanayan et al. used Life Technologies Corporation Smad2 antibody to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ].
  • western blotIn 2009, Marcela Guzman-Ayala et al. utilized Life Technologies Corporation Smad2 antibody to demostrate that the target gene expression can be promoted through Smad2/3 activation [ncbi , more ]. In 2008, Miguel A Alejandre-Alcázar et al. utilized Life Technologies Corporation Smad2 antibody to perform western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ]. Azeddine Atfi et al. used Life Technologies Corporation Smad2 antibody to study the role of disintegrin and metalloproteinase ADAM12 in TGF-beta signaling through interaction with the type II receptor [ncbi , more ] in 2007 and Weibin Shi et al. used Life Technologies Corporation Smad2 antibody to study endofin as a Smad anchor for receptor activation in BMP signaling [ncbi , more ]. In 2005, Hendrik Ungefroren et al. applied Life Technologies Corporation Smad2 antibody to study activation of Smad2 by ALK5 [ncbi , more ]. Celine Prunier et al. used Life Technologies Corporation Smad2 antibody to study the role of TGF- signaling in the phosphorylation of Smad2 and Smad3 [ncbi , more ] in 2003 and Pedro Soto et al. used Life Technologies Corporation Smad2 antibody to demonstrate that SMAD2 and SMAD7 were involved in the post-translational regulation of Muc4 [ncbi , more ]. Life Technologies Corporation Smad2 antibody was employed in 2002 to evaluate the presence and function of the family of the TGFbeta signaling molecules Smads during follicle development [ncbi , more ], to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ]and to study the involvement of Smad proteins in the TGF-beta control of BGN and SLRP gene expression [ncbi , more ]. In 2001, H Watanabe et al. utilized Life Technologies Corporation Smad2 antibody to Smad, ERK1/2, and p38 mitogen-activated protein kinase pathway cross-talka in chondrogenic ATDC5 cells [ncbi , more ].
Santa Cruz BiotechnologySanta Cruz Biotechnology SMAD2 product
  • immunocytochemistryIn 2010, Tanja Vogel et al. applied Santa Cruz Biotechnology Smad2 antibody to carry out immunofluorescence assays in order to investigate the role for transforming growth factor beta in regulating neuronal cell development [ncbi , more ]. In 2008, Amber C Liu et al. used Santa Cruz Biotechnology Smad2 antibody to investigate the regulatory role of transforming growth factor-beta in valve interstitial cell function during wound repair [ncbi , more ]. In 2005, Constance E Runyan et al. used Santa Cruz Biotechnology Smad2 antibody to study the role of internalization in transforming growth factor beta 1-induced smad2 association with smad anchor for receptor activation (SARA) and smad2-dependent signaling in human mesangial cells [ncbi , more ].
  • immunohistochemistryIn 2008, Xiao R Huang et al. utilized Santa Cruz Biotechnology Smad2 antibody to demonstrate that mice expressed a latent form of TGF-beta1 in skin keratinocytes exhibited renoprotective effects on renal fibrosis in obstructive kidney disease [ncbi , more ]. Santa Cruz Biotechnology Smad2 antibody was used in 2002 to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ], to address whether and how TGF-beta signaling becomes disrupted during human breast cancer development in vivo [ncbi , more ]and to determine the mechanism of TGF-beta resistance in endometrial carcinomas [ncbi , more ].
  • immunoprecipitationIn 2006, Ruoyun Tan et al. utilized Santa Cruz Biotechnology Smad2 antibody to investigate the regulation and mechanism of renal SnoN expression in vivo [ncbi , more ]. In 2002, Ya Chung Tian et al. employed Santa Cruz Biotechnology Smad2 antibody to examine the influence of transforming growth factor (TGF) 1 on proximal tubular epithelial cell-cell interaction, with particular emphasis on the regulation of adherens junction complex formation [ncbi , more ].
  • western blotIn 2008, Min Huei Liang et al. used Santa Cruz Biotechnology Smad2 antibody to demonstrate that lithium suppresses Smad3/4-dependent TGF-beta-responsive gene transactivation [ncbi , more ]. In 2006, Ruoyun Tan et al. utilized Santa Cruz Biotechnology Smad2 antibody to investigate the regulation and mechanism of renal SnoN expression in vivo [ncbi , more ]. In 2005, Shuanhu Zhou et al. employed Santa Cruz Biotechnology Smad2 antibody to hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells [ncbi , more ]. Annie Lacerte et al. utilized Santa Cruz Biotechnology Smad2 antibody to study the pituitary prolactin expression and cell growth inhibited by activin [ncbi , more ] in 2004 and Yoshihide Asano et al. used Santa Cruz Biotechnology Smad2 antibody to study the impaired Smad7-Smurf mediated negative regulation of TGF- signaling in scleroderma fibroblasts [ncbi , more ]. In 2003, Dirk Haller et al. used Santa Cruz Biotechnology Smad2 antibody to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ]. Santa Cruz Biotechnology Smad2 antibody was applied in 2002 to address whether and how TGF-beta signaling becomes disrupted during human breast cancer development in vivo [ncbi , more ], to detect Smad2 in human HD3 and U9 HT29 colon carcinoma sublines [ncbi , more ]and to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ].
Enzo Life Sciences
  • western blotIn 2002, Wen Bin Chen et al. used Enzo Life Sciences Smad2 antibody to study the involvement of Smad proteins in the TGF-beta control of BGN and SLRP gene expression [ncbi , more ].
Epitomics
  • western blotIn 2009, Chaoyang Jin et al. utilized Epitomics Smad2 antibody to carry out western blot analysis in order to investigate the role for Smurf2 in promoting breast cancer metastasis [ncbi , more ]. In 2008, Savita Bharathy et al. used Epitomics Smad2 antibody to perform western blot [ncbi , more ].
BD Biosciences
  • ChIP assayIn 2009, Daizo Koinuma et al. used BD Biosciences Smad2 antibody to study the roles for ETS1 and TFAP2A in the transcription induced by TGF-beta-Smad pathways [ncbi , more ].
  • immunocytochemistryIn 2001, H Watanabe et al. utilized BD Biosciences Smad2 antibody to Smad, ERK1/2, and p38 mitogen-activated protein kinase pathway cross-talka in chondrogenic ATDC5 cells [ncbi , more ].
  • immunohistochemistryIn 2009, Akiyoshi Komuro et al. employed BD Biosciences Smad2 antibody to investigate the role of transforming growth factor Beta signaling in the regulation of tumor growth [ncbi , more ].
  • immunoprecipitationIn 2001, M Furuhashi et al. applied BD Biosciences Smad2 antibody to study Smad3 activation in the transforming growth factor beta signaling pathway [ncbi , more ].
  • western blotBlanca Herrera et al. used BD Biosciences Smad2 antibody to investigate the role of BMP9 signalling via ALK2/Smad1/Smad4 pathway in ovarian cancer [ncbi , more ] in 2009 and Chaoyang Jin et al. used BD Biosciences Smad2 antibody to carry out western blot analysis in order to investigate the role for Smurf2 in promoting breast cancer metastasis [ncbi , more ]. In 2005, Nichole Boyer Arnold et al. applied BD Biosciences Smad2 antibody to study COLO-357 cell growth inhibition by TGF beta1 [ncbi , more ]. In 2004, Michael B Major et al. applied BD Biosciences Smad2 antibody to study the effect of gadd45beta3' enhancer on SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta [ncbi , more ]. In 2001, M Furuhashi et al. applied BD Biosciences Smad2 antibody to study Smad3 activation in the transforming growth factor beta signaling pathway [ncbi , more ].
Sigma-AldrichSigma-Aldrich SMAD2 product
  • immunohistochemistryIn 2005, Lei Xu et al. used Sigma-Aldrich Smad2 antibody to indicate potential therapeutic use of PDGF-D or PDGFR inhibitors to block human renal cell carcinoma tumor progression [ncbi , more ].
Source BioScience
  • EMSAIn 2005, Xiao Liang Zhang et al. applied Source BioScience Smad2 antibody to study TGF-beta1 signaling [ncbi , more ].
  • immunoprecipitationIn 2005, Xiao Liang Zhang et al. applied Source BioScience Smad2 antibody to study TGF-beta1 signaling [ncbi , more ].
Roche Applied Science
  • western blotIn 2002, Lilly Y W Bourguignon et al. used Roche Applied Science Smad2 antibody to study the effect of hyaluronan on the interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells [ncbi , more ].
Articles Reviewed
  1. David J Shields et al. (2010). "RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia".PMID 20080647
  2. Blanca Herrera et al. (2009). "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation".PMID 19996292
  3. Tanja Vogel et al. (2010). "Transforming growth factor beta promotes neuronal cell fate of mouse cortical and hippocampal progenitors in vitro and in vivo: identification of Nedd9 as an essential signaling component".PMID 19587023
  4. Akiyoshi Komuro et al. (2009). "Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling".PMID 19351925
  5. Derek P Simon et al. (2009). "Activin receptor signaling regulates prostatic epithelial cell adhesion and viability".PMID 19308291
  6. Xiaoying Liu et al. (2009). "Transforming growth factor beta1-mediated activation of the smooth muscle alpha-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-alpha via mitogen-activated protein kinase kinase 1-dependent induction of the Egr-1 transcr".PMID 19261809
  7. Marcela Guzman-Ayala et al. (2009). "Graded Smad2/3 activation is converted directly into levels of target gene expression in embryonic stem cells".PMID 19172185
  8. Chaoyang Jin et al. (2009). "Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness".PMID 19155312
  9. Minghua Wu et al. (2009). "Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma".PMID 19147827
  10. Matthew Thomas et al. (2009). "Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrot".PMID 19116361
  11. Elspeth Gold et al. (2009). "Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo".PMID 19095948
  12. Daizo Koinuma et al. (2009). "Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling".PMID 18955504
  13. Amber C Liu et al. (2008). "Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells".PMID 18832581
  14. Xiao R Huang et al. (2008). "Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease".PMID 18448597
  15. Savita Bharathy et al. (2008). "Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype".PMID 18339844
  16. Miguel A Alejandre-Alcázar et al. (2008). "TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs".PMID 18095342
  17. Min Huei Liang et al. (2008). "Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling".PMID 18077182
  18. Nina Renlund et al. (2007). "Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor".PMID 17911401
  19. Yoshihide Asano et al. (2007). "Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation".PMID 17884818
  20. Azeddine Atfi et al. (2007). "The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor".PMID 17620406
  21. Weibin Shi et al. (2007). "Endofin acts as a Smad anchor for receptor activation in BMP signaling".PMID 17356069
  22. Anna Sergeeva et al. (2006). "Display technologies: application for the discovery of drug and gene delivery agents".PMID 17123658
  23. Ruoyun Tan et al. (2006). "Downregulation of SnoN expression in obstructive nephropathy is mediated by an enhanced ubiquitin-dependent degradation".PMID 16959829
  24. Lanying Song et al. (2007). "Essential functions of Alk3 during AV cushion morphogenesis in mouse embryonic hearts".PMID 16959237
  25. Lei Xu et al. (2005). "Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model".PMID 15994946
  26. Shuanhu Zhou et al. (2005). "Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling".PMID 15845540
  27. Nichole Boyer Arnold et al. (2005). "Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein".PMID 15811853
  28. Xiao Liang Zhang et al. (2005). "Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling".PMID 15661740
  29. Takayuki Furumatsu et al. (2005). "Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment".PMID 15623506
  30. Constance E Runyan et al. (2005). "The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells".PMID 15613484
  31. Hendrik Ungefroren et al. (2005). "Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta".PMID 15546867
  32. Daniel Besser et al. (2004). "Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3".PMID 15308665
  33. Mario Schiffer et al. (2004). "A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis".PMID 15213232
  34. Annie Lacerte et al. (2004). "Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin".PMID 15031321
  35. Hiroaki Seto et al. (2004). "Distinct roles of Smad pathways and p38 pathways in cartilage-specific gene expression in synovial fibroblasts".PMID 14991070
  36. Yoshihide Asano et al. (2004). "Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts".PMID 14722617
  37. Michael B Major et al. (2004). "Identification of a gadd45beta 3' enhancer that mediates SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta".PMID 14630914
  38. Heather B Adkins et al. (2003). "Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo".PMID 12925698
  39. Celine Prunier et al. (2003). "The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation".PMID 12732634
  40. Dirk Haller et al. (2003). "Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation".PMID 12672795
  41. Pedro Soto et al. (2003). "SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-beta and interferon-gamma pathways in rat mammary epithelial cells".PMID 12668667
  42. Katrien Janssens et al. (2003). "Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein".PMID 12493741
  43. Lilly Y W Bourguignon et al. (2002). "Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells".PMID 12145287
  44. Wen Bin Chen et al. (2002). "Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells".PMID 12140283
  45. Jian Xu et al. (2002). "Stage-specific expression of Smad2 and Smad3 during folliculogenesis".PMID 12021033
  46. Trilok V Parekh et al. (2002). "Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition".PMID 12019154
  47. Ya Chung Tian et al. (2002). "Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly".PMID 12000714
  48. Chunming Dong et al. (2002). "Deficient Smad7 expression: a putative molecular defect in scleroderma".PMID 11904440
  49. Wen Xie et al. (2002). "Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study".PMID 11809701
  50. Zhongfa Yan et al. (2002). "Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1".PMID 11784716
  51. Susan Fanayan et al. (2002). "Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling".PMID 11751851
  52. M Furuhashi et al. (2001). "Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway".PMID 11438668
  53. H Watanabe et al. (2001). "Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells".PMID 11278290